This activity is not accredited for CME credit.
Dr. Jürgen Floege, co-chair of the KDIGO Work Group, reviews the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV) emphasizing diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion emphasizes the new KDIGO proteinuria treatment goal of <0.3 g/d, and the utilization of combination therapy targeting immune modulation and CKD management. In addition, Dr. Floege highlights the use of sparsentan, a dual endothelin angiotensin receptor antagonist (DEARA), now recommended as a first-line treatment where approved.
Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
Media formats available:
Details
Presenters
Overview
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!